FDA Labeling Now Aligns with the IPC and NPF Joint Position Statement on Tuberculosis Testing
FDA labeling for icotrokinra and risankizumab now leaves tuberculosis evaluation to clinical judgment, aligning with the IPC and NPF joint position statement.



Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?